Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osi-027. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 4/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 3/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 3/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 3/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 3/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 3/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 1/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | BMPR2 | Q13873 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osi-027 SCHEMBL22594988 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL25062088 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL29929993 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL976795 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL11971939 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL977589 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL977583 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL977586 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL978894 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL2697673 | 0.94 | MTOR (0.88) | MTORRICTORRPTORMAPKAP1MLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-11-05 | — | — | US | claimed |
| US-20180282818-A1 | Therapeutic Cancer Treatments Based on TP53 Gene Mutations | WISTAR INST (US) | 2018-10-04 | — | — | US | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3352755-B1 | TOPICAL COMPOSITION COMPRISING RAPAMYCIN FOR USE IN TREATING OR PREVENTING SEBORRHEIC KERATOSIS OR ACTINIC KERATOSIS | UNIV DREXEL (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3750530-B1 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | TYRNOVO LTD (IL) | 2025-12-24 | — | — | EP | disclosed |
| US-20250134837-A1 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | TYRNOVO LTD. (IL) | 2025-05-01 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250041300-A1 | PHARMACEUTICAL COMBINATION COMPRISING ABEMACICLIB AND A PI3K AND/OR A MTOR INHIBITOR FOR THE TREATMENT OF MANTLE CELL LYMPHOMA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-06 | — | — | US | disclosed |
| US-12201592-B2 | Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer | TYRNOVO LTD. (IL) | 2025-01-21 | — | — | US | disclosed |
| WO-2017062823-A1 | THERAPEUTIC CANCER TREATMENTS BASED ON TP53 GENE MUTATIONS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2017-04-13 | — | — | WO | disclosed |
| US-20170056506-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | UNIV SHANGHAI JIAOTONG (CN) | 2017-03-02 | — | — | US | disclosed |
| US-9533054-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2017-01-03 | — | — | US | disclosed |
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2015-11-12 | — | — | US | disclosed |
| US-20150031644-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | UNIV SHANGHAI JIAOTONG (CN) | 2015-01-29 | — | — | US | disclosed |
| US-8557814-B2 | mTOR inhibitor salt forms | OSI Pharmaceuticals, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130005733-A1 | COMBINATION ANTI-CANCER THERAPY | OSI Pharmaceuticals, LLC | 2013-01-03 | — | — | US | disclosed |
| US-20120108812-A1 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | OSI PHARMACEUTICALS ,INC. | 2012-05-03 | — | — | US | disclosed |
| US-20110015197-A1 | mTOR INHIBITOR SALT FORMS | OSI PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | MTOR 11/4885RICTOR 35/4885RPTOR 203/4885 |
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | CD14, TLR2, TLR4 | MTOR 1549/4885RICTOR 4606/4885RPTOR 3280/4885 |
| US-20170056506-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | ABCB4, ABCB1, LCAT | MTOR 4441/4885RICTOR 4629/4885RPTOR 4565/4885 |
| US-20250134837-A1 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | IGF1R, IRS1, MAP2K2 | MTOR 16/4885RICTOR 25/4885RPTOR 64/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | MTOR 15/4885RICTOR 48/4885RPTOR 315/4885 |
| US-20130005733-A1 | COMBINATION ANTI-CANCER THERAPY | IGF1R, IGFBP1, IRS1 | MTOR 478/4885RICTOR 184/4885RPTOR 198/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MTOR 15/4885RICTOR 149/4885RPTOR 444/4885 |
| US-20250041300-A1 | PHARMACEUTICAL COMBINATION COMPRISING ABEMACICLIB AND A PI3K AND/OR A MTOR INHIBITOR FOR THE TREATMENT OF MANTLE CELL LYMPHOMA | MALT1, MTOR, BCL6 | MTOR 2/4885RICTOR 4/4885RPTOR 24/4885 |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | ABCB4, ABCB1, LCAT | MTOR 4441/4885RICTOR 4629/4885RPTOR 4565/4885 |
| US-12201592-B2 | Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer | STAT3, IRS1, IGF1R | MTOR 7/4885RICTOR 15/4885RPTOR 25/4885 |
| US-20120108812-A1 | PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES | ALKBH5, NT5C, CYP4Z1 | MTOR 1460/4885RICTOR 3372/4885RPTOR 2274/4885 |
| US-20110015197-A1 | mTOR INHIBITOR SALT FORMS | MTOR, RPTOR, RICTOR | MTOR 1/4885RICTOR 3/4885RPTOR 2/4885 |
| US-20180282818-A1 | Therapeutic Cancer Treatments Based on TP53 Gene Mutations | TP53, TP53BP1, TP53RK | MTOR 3539/4885RICTOR 4675/4885RPTOR 4535/4885 |
| US-20150031644-A1 | AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF PREPARATION AND USES THEREOF | ABCB4, ABCB1, LCAT | MTOR 4441/4885RICTOR 4629/4885RPTOR 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.